BeOne Medicines (ONC) General Counsel Henry Buys 45,071 Shares

Lee Chan Henry, SVP and General Counsel at ONC, acquired 45,071 shares.

Reviewed by automated data checks against the source filing. How we make and check alerts

Lee Chan Henry, SVP, General Counsel at BeOne Medicines AG ($ONC), bought 45,071 shares on June 11, 2026. The trade was reported to the SEC in a Form 4 filing.

Since the trade, $ONC is up 3.8% after 1 week, up 16.8% after 1 month and up 41.8% to date (from the $260.27 close on Jun 11, 2026).

Find the original: ONC Form 4 filings on SEC EDGAR

ONC BeOne Medicines AG
$369.06 +18.66% year to date
Daily close · Oct 16, 2026

Key Points

  • Lee Chan Henry, SVP at ONC, purchased 45,071 shares on June 11, 2026, with the stock trading at $264.48.
  • Shares of ONC were trading near $264.48, with analysts maintaining strong buy ratings and targets up to $436.
  • Other institutional investors like Baker Bros. Advisors held over 8.7 million shares, while Citadel Advisors increased its holdings significantly.

Get $ONC trade alerts by text

We text you when insiders, Congress or big funds trade $ONC. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated BeOne Medicines AG alert may contain errors. Disclosures

Lee Chan Henry, the Senior Vice President and General Counsel at ONC, bought 45,071 shares of the company on June 11, 2026. This insider purchase occurred with the stock priced at $264.48 per share.

Other Institutional Activity in ONC

Baker Bros. Advisors LP maintained its position in ONC with 8,799,053 shares valued at approximately $2.61 billion. Primecap Management trimmed its holdings slightly by 5,400 shares, bringing its total to 4,975,181 shares worth about $1.48 billion. Capital International Investors reduced its stake by 955,140 shares, ending with 4,158,726 shares valued at $1.23 billion. Meanwhile, Citadel Advisors LLC nearly doubled its holdings, adding 516,719 shares to reach a total of 1,050,236 shares, valued at $306.6 million.

BeOne Medicines AG Stock Down 29.3%

ONC shares were trading near $264.48 at the time of the insider purchase. Analysts have shown confidence in the stock, with RBC Capital maintaining a 'buy' rating and setting a price target of $436 on June 2, 2026. Other analysts, including Leerink Partners and Guggenheim, have also maintained 'buy' ratings with targets of $367 and $420, respectively.

Insider Buying and Selling at BeOne Medicines AG

Several insiders, including Shalini Sharp and Xiaodong Wang, made significant purchases on June 11, 2026. Shalini Sharp acquired 18,980 shares, while Xiaodong Wang bought 193,492 shares in one transaction and 99,892 shares in another. Charles Lazelle Sawyers added 18,980 shares to his holdings. These purchases were not part of any pre-planned trading programs.

Analysts Set New Price Targets

On June 2, 2026, RBC Capital maintained its 'buy' rating on ONC with a price target of $436. Earlier, on May 15, 2026, Leerink Partners also maintained a 'buy' rating, setting a target of $367. Guggenheim and Barclays shared similar sentiments, maintaining 'buy' ratings with targets of $420 and $409, respectively. Truist Securities reiterated its 'buy' rating with a target of $413 on May 7, 2026.

Bottom Line

The recent insider buying activity by Lee Chan Henry and other executives at ONC reflects a strong belief in the company's future prospects. While insider transactions are only one piece of the puzzle, they can be a signal of confidence in the company's direction. Investors often track such moves to gauge market sentiment. However, it's important to remember that insider purchases are just part of the broader investment picture.

Source: Lee Chan Henry's Form 4 filing on $ONC (Jun 11, 2026). Find the original filing: ONC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts

Get $ONC trade alerts by text